Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) EBITDA (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed EBITDA for 3 consecutive years, with -$74.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 18.84% to -$74.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$203.5 million through Dec 2025, up 15.76% year-over-year, with the annual reading at -$203.5 million for FY2025, 15.76% up from the prior year.
  • EBITDA hit -$74.8 million in Q4 2025 for NewAmsterdam Pharma, down from -$71.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$16.6 million in Q3 2024 to a low of -$93.8 million in Q1 2024.
  • Historically, EBITDA has averaged -$51.8 million across 3 years, with a median of -$44.6 million in 2023.
  • Biggest five-year swings in EBITDA: surged 64.68% in 2024 and later plummeted 330.66% in 2025.
  • Year by year, EBITDA stood at -$49.5 million in 2023, then plummeted by 86.14% to -$92.1 million in 2024, then grew by 18.84% to -$74.8 million in 2025.
  • Business Quant data shows EBITDA for NAMS at -$74.8 million in Q4 2025, -$71.7 million in Q3 2025, and -$17.5 million in Q2 2025.